Modeling Kaempferol as a Potential Pharmacological Agent for COVID-19/PF Co-Occurrence Based on Bioinformatics and System Pharmacological Tools

Objective: People suffering from coronavirus disease 2019 (COVID-19) are prone to develop pulmonary fibrosis (PF), but there is currently no definitive treatment for COVID-19/PF co-occurrence. Kaempferol with promising antiviral and anti-fibrotic effects is expected to become a potential treatment f...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiang, Yong, Xie, Yi-Zi, Peng, Chen-Wen, Yao, Kai-Nan, Lin, Xue-Ying, Zhan, Shao-Feng, Zhuang, Hong-Fa, Huang, Hui-Ting, Liu, Xiao-Hong, Huang, Xiu-Fang, Li, Hang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214245/
https://www.ncbi.nlm.nih.gov/pubmed/35754492
http://dx.doi.org/10.3389/fphar.2022.865097

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214245/
https://www.ncbi.nlm.nih.gov/pubmed/35754492
http://dx.doi.org/10.3389/fphar.2022.865097

Ejemplares similares